Literature DB >> 30190820

Molecular pathology of cutaneous melanoma.

Léon C van Kempen1,2,1,2, Margaret Redpath1,1, Caroline Robert3,3, Alan Spatz1,2,4,1,2,4.   

Abstract

Cutaneous melanoma is associated with strong prognostic phenotypic features, such as gender, Breslow's thickness and ulceration, although the biological significance of these variables is largely unknown. It is likely that these features are surrogates of important biological events rather than directly promoting cutaneous melanoma progression. In this article, we address the molecular mechanisms that drive these phenotypic changes. Furthermore, we present a comprehensive overview of recurrent genetic abnormalities, both germline and somatic, in relation to cutaneous melanoma subtypes, ultraviolet exposure and anatomical localization, as well as pre-existing and targeted therapy-induced mutations that may contribute to resistance. The increasing knowledge of critically important oncogenes and tumor-suppressor genes is promoting a transition in melanoma diagnosis, in which single-gene testing will be replaced by multiplex and multidimensional analyses that combine classical histopathological characteristics with the molecular profile for the prognostication and selection of melanoma therapy.

Entities:  

Keywords:  biology; cutaneous melanoma; genetics; molecular pathology

Year:  2014        PMID: 30190820      PMCID: PMC6094595          DOI: 10.2217/mmt.14.23

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  193 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Modulation of activated leukocyte cell adhesion molecule-mediated invasion triggers an innate immune gene response in melanoma.

Authors:  Jeroen W J van Kilsdonk; Nozomi Takahashi; Ulrich Weidle; Helmut Burtscher; Jonathan Jarry; Mohamed R Daha; Guido W M Swart; Léon C L T van Kempen
Journal:  J Invest Dermatol       Date:  2012-02-09       Impact factor: 8.551

3.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

4.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

5.  BRAF inhibitor activity in V600R metastatic melanoma--response.

Authors:  Oliver Klein; Arthur Clements; Alexander M Menzies; Sandra O'Toole; Richard F Kefford; Georgina V Long
Journal:  Eur J Cancer       Date:  2013-03-13       Impact factor: 9.162

6.  The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Authors:  Marianne Berwick; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Homer Wilcox; Colin B Begg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

7.  BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Authors:  Victoria J Mar; Stephen Q Wong; Jason Li; Richard A Scolyer; Catriona McLean; Anthony T Papenfuss; Richard W Tothill; Hojabr Kakavand; Graham J Mann; John F Thompson; Andreas Behren; Jonathan S Cebon; Rory Wolfe; John W Kelly; Alexander Dobrovic; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

8.  E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription.

Authors:  Vicente A Torres; Julio C Tapia; Diego A Rodriguez; Alvaro Lladser; Cristian Arredondo; Lisette Leyton; Andrew F G Quest
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

9.  Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Authors:  Molly Yancovitz; Adam Litterman; Joanne Yoon; Elise Ng; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Farbod Darvishian; Paul Christos; Madhu Mazumdar; Iman Osman; David Polsky
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

Authors:  José Luis Soto; Carmen M Cabrera; Salvio Serrano; Miguel Angel López-Nevot
Journal:  BMC Cancer       Date:  2005-04-08       Impact factor: 4.430

View more
  1 in total

1.  A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia.

Authors:  Ana Carolina Porto; Tatiana Pinto Blumetti; Vinícius Fernando Calsavara; Giovana Tardin Torrezan; Cláudia Alessandra Andrade de Paula; Rute Lellis; João Pedreira Duprat Neto; Dirce Maria Carraro; J Casagrande Tavoloni Braga
Journal:  Sci Rep       Date:  2022-09-05       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.